Treatment-Naïve CLL: Phase 3 Study of Sonrotoclax Plus Zanubrutinib Compared With Venetoclax Plus Obinutuzumab in Participants With TN Chronic Lymphocytic Leukemia (CELESTIAL)
- August 6, 2024
- Clinical Trials
The CELESTIAL study is a multi-center randomized phase III trial to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia. In this study, participants with CLL, without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is considered a standard first line treatment or receive sonrotoclax plus zanubrutinib. It is hypothesized that sonrotoclax plus zanubrutinib may be better than venetoclax plus obinutuzumab in treating CLL. The main purpose of this study is to compare the duration the participants live without the CLL getting worse between participants who received venetoclax plus obinutuzumab versus sonrotoclax plus zanubrutinib. Approximately 640 participants will be included in this study around the world. Participants will have equal chance to be allocated to receive either of the treatment combinations.
